CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $29,252, lower than 95% of all stocks globally
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 67.2%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
579.64BKRW418.11M · vs all stocks (USD)
Revenue (TTM)
40.55MKRW29.25K · vs all stocks (USD)
52-Week Change
-20.98%vs all stocks
Market Capitalization
579.64BKRW418.11M · vs all stocks (USD)
Enterprise Value
651.23BKRW469.75M · vs all stocks (USD)
Price to Book (MRQ)
3.17xvs Biotechnology peers
Enterprise to EBITDA
-10.45xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Return on Assets (TTM)
-17.17%vs Biotechnology peers
Return on Equity (TTM)
10.79%vs Biotechnology peers
Revenue (TTM)
40.55MKRW29.25K · vs all stocks (USD)
Revenue per Share (TTM)
1.91KRWUpdated Sep 21, 2026Quarterly Revenue Growth
479.10%vs Biotechnology peers
Gross Profit (TTM)
40.23MKRW29.02K · vs all stocks (USD)
EBITDA (TTM)
-62.34BKRW-44.96M · vs all stocks (USD)
Net Income (TTM)
18.51BKRW13.35M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
479.07%vs Biotechnology peers
Operating Cash Flow (TTM)
-52.16BKRW-37.62M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-33.18BKRW-23.93M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
23.56MKRWFY2025 · Dec 31, 2025Gross Profit
23.56MKRWFY2025 · Dec 31, 2025Operating Income
-51.76BKRW-37.33M · vs all stocks (USD)
Pre-tax Income
-44.15BKRWFY2025 · Dec 31, 2025Income Tax Expense
-2.18BKRWFY2025 · Dec 31, 2025Net Income
-41.97BKRWFY2025 · Dec 31, 2025EBIT
-42.27BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-41.87BKRWFY2025 · Dec 31, 2025Research & Development
35.65BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
5.86BKRWFY2025 · Dec 31, 2025Other Operating Expenses
269.96MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
1.13BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
1.88BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-41.97BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-44.87BKRWFY2025 · Dec 31, 2025Free Cash Flow
-45.56BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.07BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-41.97BKRWFY2025 · Dec 31, 2025Stock-based Compensation
867.79MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-3.74BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-73.11MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
52.39MKRWFY2025 · Dec 31, 2025Capital Expenditures
-696.27MKRWFY2025 · Dec 31, 2025Purchase of Investments
-97.63BKRWFY2025 · Dec 31, 2025Sale of Investments
70.00BKRWFY2025 · Dec 31, 2025Other Investing Activity
-20.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-28.32BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
49.57BKRWFY2025 · Dec 31, 2025Shares Outstanding
21.23MSharesUpdated Sep 21, 2026Float Shares
15.48MSharesUpdated Sep 21, 2026% Held by Insiders
15.82%vs all stocks
% Held by Institutions
10.58%vs all stocks
Total Cash (MRQ)
251.91BKRW181.71M · vs all stocks (USD)
Total Cash per Share (MRQ)
11.68KKRWUpdated Sep 21, 2026Total Debt (MRQ)
96.20BKRW69.39M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5172xvs Biotechnology peers
Current Ratio (MRQ)
3.13xvs Biotechnology peers
Book Value per Share (MRQ)
8.62KKRWUpdated Sep 21, 2026Total Assets
169.32BKRW122.14M · vs all stocks (USD)
Total Current Assets
134.37BKRWFY2025 · Dec 31, 2025Total Liabilities
38.44BKRWFY2025 · Dec 31, 2025Total Non-current Assets
34.95BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
22.83BKRWFY2025 · Dec 31, 2025Total Current Liabilities
15.61BKRWFY2025 · Dec 31, 2025Cash Equivalents
4.07BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.07BKRWFY2025 · Dec 31, 2025Other Short-term Investments
128.54BKRWFY2025 · Dec 31, 2025Accounts Receivable
558.17KKRWFY2025 · Dec 31, 2025Short-term Debt
2.78BKRWFY2025 · Dec 31, 2025Other Current Liabilities
-140.00KRWFY2025 · Dec 31, 2025Long-term Debt
22.72BKRWFY2025 · Dec 31, 2025Common Stock (Book)
2.12BKRWFY2025 · Dec 31, 2025Retained Earnings
18.22BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
130.89BKRW94.41M · vs all stocks (USD)
52-Week Low
26.20KKRWUpdated Sep 21, 202652-Week High
146.60KKRWUpdated Sep 21, 202652-Week Change
-20.98%vs all stocks
50-Day MA
55.02KKRWUpdated Sep 21, 2026200-Day MA
84.36KKRWUpdated Sep 21, 2026Avg 10-Day Volume
69.67KSharesUpdated Sep 21, 2026Avg 30-Day Volume
119.45KSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-2.02KKRWUpdated Sep 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 67.2%)Significant
Gross margin: 1.00Industry median: 0.67Industry P95: 1.00Peers compared: 260
Operating margin is -63691%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -636.91Industry median: -0.38Industry P5: -43.63Peers compared: 260
Profit margin is 45646.4%, higher than 95% of its Biotechnology peers (median -47.7%)Significant
Profit margin: 456.464Industry median: -0.48Industry P95: 0.42Peers compared: 260
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 13,352,408.856Operating Cash Flow (USD, TTM): -37,622,748.254
Financial Health
Altman Z-Score 9.22: safe zoneNotable
Altman Z-Score: 9.22
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $29,252, lower than 95% of all stocks globallySignificant
Revenue (USD): 29,251.82Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Canopy Growth Corporation
Tier 1ProductionApproval-Gated PipelineFlowRule
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Wintao Communications Co.
3 interpretationsDown-Close Share With Multi-Year Earnings DecreaseDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Dongguan Eontec Co., Ltd.
3 interpretationsDown-Close Share With Multi-Year Earnings DecreaseDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Piesat Information Technology Inc.
3 interpretationsDown-Close Share With Multi-Year Earnings DecreaseDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated